Needham & Company Reaffirms Buy Rating on Pernix Therapeutics Holdings (PTX)

By admin | 6 years ago

Pernix Therapeutics Holdings (NYSE: PTX)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company in a report released on Wednesday.

Shares of Pernix Therapeutics Holdings remained flat at $7.52 during during mid-day trading trading on Wednesday. Pernix Therapeutics Holdings has a one year low of $6.07 and a one year high of $11.50. The company has a market cap of $218.6 million and a P/E ratio of 22.51.

Other equities research analysts have also recently issued reports about the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Pernix Therapeutics Holdings in a research note to investors on Monday, April 9th. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Pernix Therapeutics Holdings to $16.00 in a research note to investors on Thursday, April 5th.

Pernix Therapeutics Holdings, Inc., formerly Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet unmet medical needs primarily in pediatrics.

About the author